Clinical Trials

The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.

The purpose of this study is to examine the period prevalence, independent risk factors and consequences of diarrhea in the ICU setting.

The purpose fo this study is to study changes in the fecal microbiome in patients with non-infectious diarrhea.

To understand the mechanisms associated with diarrhea in patients receiving conditioning chemotherapy prior to autologous stem cell transplantation and to test the effects of the studied therapies on mechanisms that may be involved in the pathophysiology of diarrhea associated with conditioning chemotherapy.

To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects with IBS-D.

The purpose of this study is to evaluate the changes in bowel movements in patients with multiple myeloma receiving conditioning cheomotherapy for autologous stem cell transplantation (SCT). 

This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.

608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.

The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid excretion in patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid excretion. The investigators aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with Colesevelam.

The purpose of this study is to determine if people with diarrhea predominant IBS (IBS-D) from the community are interested in making dietary modifications to control their symptoms.  Also to determine if people with IBS-D from the community have tried dietary modifications to control their symptoms and if they have, which diets they have tried.

The purpose of this study is to understand the role of genetics (inherited genes from biological parents) and expression of genes and proteins in the lining of the intestine and colon in the development of diarrhea in patients with irritable bowel syndrome with or without bile acid malabsorption. 

The purpose of this study is to measure 48 hour fecal bile acids in IBS-D adolescents and compare it to HC; measure serum C4 and FGF-19 in adolescents with IBS-D and HC and compare it to 48 hour fecal bile acid loss; measure primary bile acids concentration in 48 hour stool collection in adolescents with IBS-D and compare it to HC.

We aim to validate fasting serum C4 and primary bile acids from a single stool sample (individually or in combination) in 65 patients with diarrhea predominant irritable bowel syndrome (IBS-D), 30 healthy volunteers, and 12 patients with terminal ileal resection > 10 cm. First, we will validate the combined serum C4 and primary bile acids in patients with IBS-D without BAM, IBS-D with BAM, and healthy volunteers by comparing the individual or combined serum and stool test to documented 48 hour total fecal bile acid (current gold standard to diagnose bile acid malabsorption in the USA). Second, we will evaluate ...

The purpose of this study of sulfasalazine is to see how well it works in preventing acute diarrhea in patients with cancer who are undergoing pelvic radiation therapy. Sulfasalazine may relieve diarrhea in patients with cancer who are undergoing pelvic radiation therapy.

The overall hypothesis of this research study is that gluten intake alters intestinal barrier function in patients with Irritable Bowel Syndrome (IBS) diarrhea who also exhibit non-celiac gluten sensitivity (NCGS).

To compare with a randomized trial (n=15 per treatment group), effects of colesevelam and placebo treatment, on colonic transit, bowel functions, permeability and tight junction expression in rectosigmoid mucosa of IBS-D with Bile Acid Malabsorption.

The purpose of this study is to evaluate the safety and effectiveness of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

The purpose of this study is to compare ridinilazole with vancomycin as comparator to treat Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease.

The purpose of this study is to develop a resource (bank) of biospecimens and data collected from individuals with functional gastrointestinal disorders (FGID) to facilitate discovery and development of novel microbial biomarkers of disease and response to treatment, and novel targeted therapeutic strategies for FGID.  

The objective of this study is to compare the safety, tolerance and efficacy of BLI800 to a PEG based preparation prior to colonoscopy in adolescent patients.

The purpose of this study is to evaluate abdominal pain response to BOS-589 in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) after 4 weeks of treatment, and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).

The purpose of this study is to:

1. To evaluate the pharmacogenomic profile (PGx) by genotyping 22 genes, including the CYP2D6 genotype, in patients with functional GI disorders.
2. To assess the impact of PGx testing on prescriber patterns in this practice.
3. To explore the impact of PGx testing on patient outcomes after an assessment in this practice.